Drugs / Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive Hematopoietic Progenitor Cells
Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive Hematopoietic Progenitor Cells
targets CCR5 via inhibition
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02797470 | Jun 2016 → May 2021 overdue | Burkitt lymphoma, HIV infectious disease, Hodgkins lymphoma, follicular lymphoma +3 | AIDS Malignancy Consortium | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive Hematopoietic Progenitor Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02797470 ↗ |
| Action | Inhibit | “prevent new immune cells from getting infected with HIV-1” NCT02797470 ↗ |
| Route | Intravenous | “Patients undergo intravenous (IV) infusion of lentivirus vector CCR5 shRNA/TRIM5alpha/TAR decoy-transduced autologous CD34-positive hematopoietic progenitor cells over 1 hour.” NCT02797470 ↗ |
| Target | CCR5 | “CCR5 shRNA” NCT02797470 ↗ |